[1] Sangu P,Ranasinghe I, Aliprandi B,et al.Trends and predictors of rehospitalisation following an acute coronary syndrome:report from the Australian and New Zealand population of the Global Registry of Acute Coronary Events(GRACE)[J].Heart,2012,98(23):1728-1731. [2] Hasan A,Hakan O,Ali K,et al. The effect of high-dose clopidogrel treatment in patients with clopidogrel resistance(The EFFICIENT Trial)[J]. Int J Cardiol,2012,157(3):374-380. [3] 崔同涛,于汇民,董太明,等.二磷酸腺苷诱导血小板聚集率与急性冠状动脉综合征患者支架置入预后的关系[J].中国介入心脏病学杂志,2012,20(6):301-306. [4] 谢爽,徐波,杨跃进,等.冠状动脉介入治疗用药致上消化道出血的病例分析[J].中国药物警戒,2010,7(5):277-279. [5] Lars W,Stefan J,Robert F,et al.Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial[J].Lancet,2010,376(9749):1320-1328. [6] Lars W,Richard C,Andrzej B,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med,2009,361(11):1045-1057. [7] Antman M,Hand M,Armstrong W,et a1.2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol,2008,51(2):210-247. [8] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. [9] Pena A,Collet P,Hulot S,et al.Can we override clopidogrel resistance[J].Circulation,2009,119(21):2854-2857. [10] Wang X D,Zhang D F,Liu X B,et al.Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance[J].Eur J Intern Med,2012,23(1):48-53. |